VolitionRx Limited Announces Second Quarter 2020 Financial Results and Business Update
VolitionRx Limited Schedules Second Quarter 2020 Earnings Conference Call and Business Update
Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test
VolitionRx Releases Business Update Video and Announces Addition to the Russell 3000® and Russell Microcap® Indexes
Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference
VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock
VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock
VolitionRx Announces Proposed Underwritten Public Offering of Common Stock
VolitionRx To Present First Data on Nu.Q™ Capture Performance and Nu.Q™ Assay Performance in Lung Cancer and Blood Cancer at the 2020 ASCO Annual Meeting
VolitionRx Limited Announces First Quarter 2020 Financial Results and Business Update
